SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 227 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.34 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $224,000 | -97.8% | 8,900 | -97.6% | 0.00% | -95.2% |
| Q3 2019 | $10,356,000 | -19.8% | 376,892 | -3.5% | 0.02% | -16.0% |
| Q2 2019 | $12,920,000 | +104.4% | 390,426 | +116.4% | 0.02% | 0.0% |
| Q1 2019 | $6,320,000 | +27.6% | 180,378 | +21.0% | 0.02% | +13.6% |
| Q4 2018 | $4,954,000 | -22.2% | 149,123 | +17.9% | 0.02% | -4.3% |
| Q3 2018 | $6,370,000 | -15.8% | 126,519 | +0.1% | 0.02% | -20.7% |
| Q2 2018 | $7,565,000 | -11.4% | 126,395 | -32.2% | 0.03% | -14.7% |
| Q1 2018 | $8,539,000 | +13.3% | 186,451 | -1.4% | 0.03% | +13.3% |
| Q4 2017 | $7,534,000 | -0.4% | 189,048 | 0.0% | 0.03% | -9.1% |
| Q3 2017 | $7,562,000 | -18.3% | 189,048 | -11.9% | 0.03% | -21.4% |
| Q2 2017 | $9,252,000 | +41.9% | 214,669 | +3.1% | 0.04% | +44.8% |
| Q1 2017 | $6,519,000 | +1490.0% | 208,270 | +582.9% | 0.03% | +1350.0% |
| Q4 2015 | $410,000 | – | 30,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ASHFORD CAPITAL MANAGEMENT INC | 921,962 | $33,402,683 | 5.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 423,500 | $15,326,465 | 4.28% |
| ARMISTICE CAPITAL, LLC | 4,350,000 | $157,600,500 | 2.27% |
| S&T BANK/PA | 223,775 | $8,107 | 1.46% |
| Aristotle Capital Boston, LLC | 1,155,149 | $41,851,071 | 1.29% |
| Tributary Capital Management, LLC | 353,671 | $12,813,500 | 1.19% |
| Bridge City Capital, LLC | 62,790 | $2,274,882 | 1.14% |
| RICE HALL JAMES & ASSOCIATES, LLC | 551,285 | $19,973,056 | 1.14% |
| Intrinsic Edge Capital Management LLC | 289,704 | $10,495,976 | 1.05% |
| Parkman Healthcare Partners LLC | 131,878 | $4,777,940 | 1.04% |